The science behind side-effect-low iron therapy
Through innovative formulation of iron succinate, we have solved the biggest obstacle to iron deficiency: the balance between maximum absorption and patient well-being.
Ferrous Succinate
A molecule optimized for humans
Most iron preparations on the market today use compounds that are difficult for the body to break down, leading to nausea, stomach pain and constipation in up to 60% of patients.
Our Bio Vitos solution
uses a unique form of iron succinate. Thanks to its specific chemical structure, the iron is absorbed effectively in the small intestine without irritating the mucous membranes of the gastrointestinal tract.
The result:
A clinically documented profile with low significant side effects.
Clinical Validation & Expertise
World-class research
Our technology is not just a theory – it is currently being tested in extensive clinical studies led by some of Sweden’s leading experts.
Professor Fredrik Nyström
Under the leadership of Professor Fredrik Nyström at Linköping University, the FERITUP (women) and FERMANUP (men) studies are being conducted. With 80 participants in each study, we ensure the statistical power required for global regulatory approvals.
Milestone: Final analysis reports will be completed in March 2026.
Intellectual Property Rights (IP)
A protected value in 26 countries
Bio Vitos Pharma owns a strong and growing patent portfolio that secures our exclusivity in the market.
Our Patents
We hold approved patents in 26 European countries specifically for the treatment of iron deficiency in heart failure. This creates a powerful barrier to competitors and secures long-term revenue streams for our shareholders.
Brands
Our products FE-MININ™ , MAXFERMAN™ and SUCCIFER® are registered trademarks that represent the gold standard in modern iron therapy for both women and men.
Regulatory Road
Medical Health Claims
We follow the regulatory path through EFSA (European Food Safety Authority). An approval from EFSA acts as a “regulatory passport” that gives us the immediate right to market our products with scientific health claims in all 27 EU countries.
Status
Submission of three parallel applications will take place in the spring of 2026 with expected approval by midsummer of the same year.